Free tool
FAERS Monitor: Kadcyla
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125427 or its brand name (Kadcyla, Ado-Trastuzumab Emtansine). Reports on generic versions are filed under their own applications.
Reports
8,459
Serious
6,979
83% of reports
Hospitalization
2,172
Death reported
1,171
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- disease progression807
- fatigue759
- nausea741
- off label use647
- diarrhoea605
- death565
- thrombocytopenia485
- neuropathy peripheral457
- platelet count decreased438
- headache436
- metastases to central nervous system409
- drug ineffective406
- vomiting352
- pyrexia338
- epistaxis322
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 11 |
| 2013 | 157 |
| 2014 | 296 |
| 2015 | 671 |
| 2016 | 371 |
| 2017 | 377 |
| 2018 | 456 |
| 2019 | 455 |
| 2020 | 619 |
| 2021 | 889 |
| 2022 | 1,039 |
| 2023 | 1,091 |
| 2024 | 1,085 |
| 2025 | 635 |
| 2026 | 307 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,700 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| metastases to central nervous systemSignal | 409 | 81.4 | 73.9 | 31,389 |
| disease progressionSignal | 807 | 17.1 | 16.0 | 12,176 |
| neuropathy peripheralSignal | 457 | 12.0 | 11.0 | 4,595 |
| thrombocytopeniaSignal | 485 | 10.8 | 9.9 | 4,320 |
| epistaxisSignal | 322 | 10.7 | 9.7 | 2,834 |
| platelet count decreasedSignal | 438 | 10.3 | 9.4 | 3,653 |
| pyrexiaSignal | 338 | 2.4 | 2.2 | 288 |
| fatigueSignal | 759 | 2.4 | 2.3 | 658 |
| diarrhoeaSignal | 605 | 2.3 | 2.2 | 473 |
| nauseaSignal | 741 | 2.3 | 2.2 | 582 |
| vomiting | 352 | 1.9 | 1.7 | 143 |
| off label use | 647 | 1.8 | 1.7 | 257 |
| headache | 436 | 1.7 | 1.6 | 137 |
| death | 565 | 1.6 | 1.5 | 143 |
| drug ineffective | 406 | 0.8 | 0.7 | 31 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.